Advances in GIST Management

(P 23) GENOMIC COMPLEXITY AS A BIOMARKER FOR ADJUVANT IMATINIB TREATMENT IN HIGH-RISK GASTROINTESTINAL STROMAL TUMOR

(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)

(P 25) PREDICTING IMATINIB RESPONSES USING IN VITRO MODELS OF PDGFRA-MUTANT GASTROINTESTINAL STROMAL TUMOR

(P 26) PHASE 1 STUDY OF IDRX-42 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS RESISTANT TO PRIOR SYSTEMIC THERAPY: EARLY RESULTS

(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST

(P 28) RETROSPECTIVE ANALYSIS OF SUCCINATE DEHYDROGENASE (SDH)-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST) OUTCOMES: AN INTERNATIONAL STUDY OF 256 PATIENTS

(P 29) COMBINATION TREATMENT WITH TEMOZOLOMIDE AND THE DEATH RECEPTOR-5 AGONIST INBRX-109 EFFECTIVELY TARGETS SUCCINATE DEHYDROGENASE -DEFICIENT GASTROINTESTINAL STROMAL TUMOR

(P 30) FINANCIAL DIFFICULTIES EXPERIENCED BY DUTCH GASTROINTESTINAL STROMAL TUMOR (GIST) PATIENTS: DATA FROM A CROSS-SECTIONAL MULTICENTER STUDY

(P 31) NEOADJUVANT IMATINIB IN LOCALLY ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) IS EFFECTIVE AND SAFE: RESULTS FROM A PROSPECTIVE SINGLE CENTER STUDY WITH 108 PATIENTS

(P 32) IMPROVEMENT OF QUALITY AND TEXTBOOK OUTCOMES OF GASTRIC GASTROINTESTINAL STROMAL TUMOR (GIST) RESECTIONS IN THE PAST 13 YEARS; THE INFLUENCE OF MINIMAL INVASIVE SURGERY (MIS)

(P 33) LONGITUDINAL FOLLOW UP OF GASTROINTESTINAL STROMAL TUMORS:DATA FROM THE LIFE RAFT GROUP INTERANTIONAL PATIENT REGISTRY

(P 34) RIPRETINIB IN COMBINATION WITH OTHER TKIS IN CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A MULTI-CENTER RETROSPECTIVE ANALYSIS

(P 35) GENOMIC ALTERATIONS IN ADVANCED GASTROINTESTINAL STROMAL TUMORS AS REVEALED BY COMPREHENSIVE GENOMIC PROFILING TESTS

(P 37) DISSECTING THE ROLE OF EXTRACELLULAR VESICLES IN THE MANAGEMENT OF GIST

(P 38) EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMORS: A MULTICENTER RETROSPECTIVE STUDY

(P 39) MANAGEMENT PRACTICES OF GASTROINTESTINAL STROMAL TUMORS: A QUESTIONNAIRE SURVEY OF GENERAL SURGEONS IN CHINA

(P 40) LONG TERM OUTCOMES OF NEOADJUVANT IMATINIB AND SURGICAL RESECTION OF RECTAL GASTROINTESTINAL STROMAL TUMOURS

(P 41) GENOMIC ANALYSIS OF SECONDARY KIT MUTATIONS IN CHINESE PATIENTS WITH IMATINIB-RESISTANT ADVANCED GASTROINTESTINAL STROMAL TUMORS USING NEXT-GENERATION SEQUENCING (NGS)

(P 42) THE EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GISTS): A SINGLE-INSTITUTION ANALYSIS

(P 43) UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN AS A POTENTIAL NEXT GENERATION MOLECULAR TARGET FOR TREATMENT OF GASTROINTESTINAL STROMAL TUMOR

(P 44) RIPRETINIB FOR THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBORING KIT SECONDARY MUTATIONS: A MULTICENTER, RETROSPECTIVE STUDY

(P 45) THE LONG-TERM EFFECT OF IMATINIB WITH HEPATIC RESECTION OR OTHER LOCAL TREATMENT FOR GIST LIVER METASTASES

(P 46) CIRCULATING TUMOR DNA (CTDNA) ANALYSES AND RESISTANCE MECHANISMS EXPLORATION OF KIT-MUTANT GASTROINTESTINAL STROMAL TUMORS (GISTS) TREATED WITH AVAPRITINIB OR RIPRETINB

(P 47) PATIENT SURVIVAL IN METASTATIC GIST WITH IMATINIB-SENSITIVE MUTATIONS: REAL WORLD DATA FROM GERMAN REFERRAL CENTER (2008-2021)

(P 48) SIGNIFICANCE OF MONITORING PLASMA CONCENTRATION OF RIPRETINIB IN CHINESE PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS

(P 49) EFFICACY OF RIPRETINIB IN A MULTICENTER EXPANDED ACCESS PROGRAM IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBOURING NON-KIT EXON 11 MUTATIONS.

(P 50) CHARACTERIZATION OF A FAMILIAL GIST KINDRED INTOLERANT TO IMATINIB